Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
1.020
0.00 (0.00%)
At close: Oct 29, 2026, 4:00 PM EDT
1.020
0.00 (0.00%)
Pre-market: Oct 30, 2026, 7:15 AM EDT
Annovis Bio Employees
Annovis Bio had 7 employees as of December 31, 2025. The number of employees decreased by 8 or 53.33% compared to the previous year. That makes Annovis Bio the 40,905th largest employer in the world and 6,244th in the United States.
Employees
7
Change (1Y)
-8
Growth (1Y)
-53.33%
Revenue / Employee
n/a
Profits / Employee
-$7,074,895
Market Cap
43.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | -8 | -53.33% | 7 | 0 |
| Dec 31, 2024 | 15 | -1 | -6.25% | 8 | 7 |
| Dec 31, 2023 | 16 | 11 | 220.00% | 6 | 10 |
| Dec 31, 2022 | 5 | 2 | 66.67% | 5 | 0 |
| Dec 31, 2021 | 3 | 1 | 50.00% | 3 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| Actinium Pharmaceuticals | 27 |
| INmune Bio | 21 |
| ImageneBio | 18 |
| Instil Bio | 17 |
| Serina Therapeutics | 16 |
| Apollomics | 14 |
| Dogwood Therapeutics | 8 |
ANVS News
- 1 day ago - Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026 - GlobeNewsWire
- 8 days ago - Annovis to Attend the CTAD 2026 with Three Presentations - GlobeNewsWire
- 23 days ago - Annovis Bio Proxy statement: Proxy filing - Filings
- 5 weeks ago - Annovis Bio announces partnership with Weave Bio - TheFly
- 5 weeks ago - Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease - GlobeNewsWire
- 7 weeks ago - Annovis Bio Proxy statement: Proxy filing - Filings
- 1 month ago - Annovis Bio Transcript: Investor update - Transcripts
- 2 months ago - Annovis Bio price target lowered to $7 from $8 at Roth Capital - TheFly